Table 3.
Characteristics of the UC cohort.
| Variable | Without symptoms of anxiety/depression (n = 69) | With symptoms of anxiety/depression (n = 44) | p value |
|---|---|---|---|
| Age (years) median (IQR) | 35 (27, 50) | 50 (33, 55) | 0.0037 |
| Women (%) | 40 (52.6) | 15 (34.1) | 0.0587 |
| Disease duration (months) median (IQR) | 29 (20, 90) | 36 (7.5, 84) | 0.8354 |
| Tobacco use, n | |||
| Never | 55 (72.4) | 28 (63.6) | 0.5891 |
| Quitted | 15 (19.7) | 12 (27.3) | |
| Current | 6 (7.9) | 4 (9.1) | |
| Disease activity, n (%) | |||
| Remission | 8 (10.5) | 2 (4.5) | 0.5095 |
| Mild | 10 (13.2) | 4 (9.1) | |
| Moderate | 12 (15.8) | 6 (13.6) | |
| Severe | 46 (60.5) | 32 (72.7) | |
| Disease distribution, n (%) | |||
| E1 | 8 (10.5) | 3 (6.8) | 0.6591 |
| E2 | 22 (29.0) | 11 (25.0) | |
| E3 | 46 (60.5) | 30 (68.2) | |
| Extra-intestinal manifestations, n (%) | 8 (10.5) | 4 (9.1) | > 0.9999 |
| Surgeries, n (%) | 4 (5.3) | 10 (22.7) | 0.0067 |
| Mayo score, median (IQR) | 8 (7, 9) | 10 (8.5, 11) | 0.0017 |
| UCEIS, median (IQR) | 4 (3, 5) | 6 (4.75, 7) | < 0.0001 |
| WBC (× 109/L), median (IQR) | 7.21 (5.03, 8.90) | 6.90 (5.78, 9.16) | 0.9177 |
| ALB(g/L), median (IQR) | 40.1 (32.5, 44.0) | 34.0 (28.2, 41.7) | 0.0070 |
| CRP (mg/L), median (IQR) | 11.4 (3.1, 38.2) | 16.7 (7.2, 43.0) | 0.7314 |
| ESR (mm/h), median (IQR) | 27 (16, 47) | 41 (24, 66) | 0.1377 |
| Mesalazine, n (%) | 48 (63.2) | 21 (47.7) | 0.1259 |
| Corticosteroid, n (%) | 20 (26.3) | 21 (47.7) | 0.0273 |
| Immunomodulator, n (%) | 10 (13.2) | 6 (13.6) | > 0.9999 |
| Anti-TNF, n (%) | 6 (7.9) | 4 (9.1) | > 0.9999 |
UC ulcerative colitis, UCEIS ulcerative colitis endoscopic index of severity, WBC white blood count, ALB albumin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNF tumor necrosis factor, IQR interquartile range.